
Swiss biotech Idorsia (SIX: IDIA) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to daridorexant for the treatment of insomnia disorder in patients 10 to <18 years of age.
The designation provides for intensive FDA guidance and closer collaboration on the development of daridorexant in children and adolescents. Daridorexant is a next-generation dual orexin receptor antagonist (DORA) that selectively reduces wake drive rather than broadly inhibiting brain activity. Idorsia designed daridorexant with an optimized pharmacokinetic profile to provide efficacy throughout the night while minimizing residual exposure the following morning. This differentiated profile has been associated with improvements in sleep parameters and daytime functioning in adults with insomnia disorder and may be particularly relevant for children and adolescents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze